Pfizer Inc. and BioNTech SE started an international study with 4,000 volunteers to evaluate the safety and effectiveness of their COVID-19 vaccine in healthy pregnant women.
Findings from a Phase III long-term extension study show a once-daily therapy consisting of relugolix with estradiol and norethindrone acetate leads to clinically meaningful reductions in menstrual pain and non-menstrual pelvic pain over one year in women with endometriosis.
Vaccinating nine in 10 girls under the age of 15 years against cervical cancer, and improved screening and treatment of women could reduce infections by 40% and save 5 million lives by 2050, the World Health Organization (WHO) said.
ViiV Healthcare announced that an independent data safety monitoring board (DSMB) recommended the early unblinding of data from the HIV Prevention Trials Network 084 trial of the investigational, long-acting injectable cabotegravir for HIV prevention in women.
ViiV Healthcare announces investigational injectable cabotegravir is superior to oral standard of care for HIV prevention in women Interim analysis from HPTN 084 study shows long-acting injectable cabotegravir administered every two months is 89% more effective than daily pills in preventing HIV acquisition in women Findings follow data from HPTN 083, a partner HIV prevention […]
The Healthcare Technology Report announced the Top 25 Women Leaders in Biotechnology of 2020.
Infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) during pregnancy does not appear to increase the risk of complications during delivery or negatively impact the health of newborns, according to a new JAMA study.
A roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for Covid-19, the illness caused by the virus.
Boehringer Ingelheim’s Animal Health USA division will reimburse $379,089 in back pay and interest to 75 female employees to resolve alleged wage discrimination at the company’s St. Joseph, Missouri, facility.
German drugs and pesticides group Bayer will pay around $1.6 billion to settle the majority of U.S. claims involving the Essure birth-control device.